{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for amphotericin root_notes_note in Note (approximate match)
Status:
US Previously Marketed
First approved in 1953
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Protoveratrine B is one of two alkaloids isolated from the plant Veratrum albumen. The main effect of both alkaloids is vasodilation in all vascular beds thereby reducing blood pressure. In the 1950's it was recognized that Protoveratrine B is the preferred compound which can be administered at significantly higher doses before the patient begins to vomit.
Status:
US Previously Marketed
First approved in 1953
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Protoveratrine B is one of two alkaloids isolated from the plant Veratrum albumen. The main effect of both alkaloids is vasodilation in all vascular beds thereby reducing blood pressure. In the 1950's it was recognized that Protoveratrine B is the preferred compound which can be administered at significantly higher doses before the patient begins to vomit.
Status:
US Previously Marketed
First approved in 1953
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Protoveratrine B is one of two alkaloids isolated from the plant Veratrum albumen. The main effect of both alkaloids is vasodilation in all vascular beds thereby reducing blood pressure. In the 1950's it was recognized that Protoveratrine B is the preferred compound which can be administered at significantly higher doses before the patient begins to vomit.
Status:
Possibly Marketed Outside US
Source:
M017
(2024)
Source URL:
First approved in 2024
Source:
M017
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
M017
(2024)
Source URL:
First approved in 2024
Source:
M017
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Boronophenylalanine B-10 (also known as BPA), a boron delivery agent, is used in boron-neutron capture therapy (BNCT) for metastatic melanomas and other tumors. BNCT is a therapeutic modality for malignant tumors using the nuclear capture and fission reactions that occur when boron-10 (10B) is irradiated with neutron beams. This reaction, in theory, only kills 10B-containing cells because the destructive effect of the alpha particles and lithium nuclei, which are produced by the reaction, is limited to the immediate vicinity of the reaction, approximately one cell diameter. Boronophenylalanine is localized to cells through transporter-mediated mechanisms. Aromatic amino acid transporters, ATB0,+, as well as LAT1 contribute significantly to the tumor accumulation of BPA at clinical dose.
Status:
Possibly Marketed Outside US
Source:
Danil by Jiangsu Chenpai Bond Pharmaceutical Co.,Ltd.
(2024)
Source URL:
First approved in 2024
Source:
Danil by Jiangsu Chenpai Bond Pharmaceutical Co.,Ltd.
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
TECHNETIUM TC 99M SESTAMIBI
Source URL:
First approved in 1990
Source:
NDA019785
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions: